Home » Topics » Conferences, BioWorld Science

Conferences, BioWorld Science
RSS

Design and synthesis of cycloheptylurea factor Xa inhibitors reported by DuPont

Sep. 16, 1998

Organon designs novel acylguanidine-containing thrombin inhibitors

Sep. 16, 1998

Potent and selective 5-HT1B/1D antagonists designed by Merck KGaA

Sep. 16, 1998

Novel glucagon receptor antagonist with potential in treating type I/type II diabetes

Sep. 15, 1998

Pierre Fabre describes pharmacological profile of F-11440 -- new high-efficacy 5-HT1A agonist

Sep. 15, 1998

Potent mGluR1/mGluR5 receptor antagonist presented by Lilly at EFMC symposium

Sep. 15, 1998

SmithKline Beecham research leads to discovery of potent and selective 5-HT7 antagonists

Sep. 15, 1998

F-12682: new 5-HT1B/1D receptor inverse agonist for depression

Sep. 15, 1998

New Asta development candidate represents new type of PDE4 inhibitor

Sep. 15, 1998

Early clinical trial results reported for cilansetron at recent congress

Sep. 14, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...